{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:52:18Z","timestamp":1790722338997,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.autrev.2008.11.003","type":"journal-article","created":{"date-parts":[[2008,11,26]],"date-time":"2008-11-26T13:34:41Z","timestamp":1227706481000},"page":"274-280","source":"Crossref","is-referenced-by-count":94,"title":["Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal"],"prefix":"10.1016","volume":"8","author":[{"given":"Roberto","family":"Caporali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Bobbio","family":"Pallavicini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Filippini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gorla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marchesoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio Giulio","family":"Favalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlomaurizio","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2008.11.003_bib1","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1056\/NEJMra040226","article-title":"Therapeutic strategies for rheumatoid arthritis","volume":"350","author":"O'Dell","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2008.11.003_bib2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choi","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2008.11.003_bib3","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of antitumour necrosis factor alpha monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.003_bib4","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.autrev.2005.09.007","article-title":"Molecular mechanisms of TNF-alpha-induced apoptosis in naive and memory T cell subsets","volume":"5","author":"Gupta","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2008.11.003_bib5","first-page":"705","article-title":"ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology","volume":"26","author":"van Gestel","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2008.11.003_bib6","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(89)92442-2","article-title":"Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis","volume":"1","author":"van der Heijde","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2008.11.003_bib7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2008.11.003_bib8","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2008.11.003_bib9","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.003_bib10","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1002\/art.21503","article-title":"Progress toward the cure of rheumatoid arthritis? The BeSt study","volume":"52","author":"Weisman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.003_bib11","first-page":"819","article-title":"Switching between biological agents","volume":"22","author":"van Vollenhoven","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2008.11.003_bib12","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for treatment of rheumatoid arthritis","volume":"370","author":"Smolen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2008.11.003_bib13","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1136\/ard.2007.072447","article-title":"The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomized control trials and clinical practice","volume":"66","author":"Kievit","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2008.11.003_bib14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/art.10817","article-title":"Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis","volume":"48","author":"Sokka","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.003_bib15","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1002\/art.22193","article-title":"Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials","volume":"54","author":"Zink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.003_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/rheumatology\/kei056","article-title":"Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness","volume":"44","author":"Wolfe","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2008.11.003_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/BOR.0b013e3282f50eb1","article-title":"The role of drug and disease registries in rheumatic disease epidemiology","volume":"20","author":"Kremer","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2008.11.003_bib18","first-page":"413","article-title":"Anti-TNF treatment for rheumatoid arthritis","volume":"24","author":"Valesini","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2008.11.003_bib19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/BOR.0b013e3282f4b392","article-title":"The safety of anti-tumor necrosis factor therapy in rheumatoid arthritis","volume":"20","author":"Askling","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2008.11.003_bib20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.berh.2006.06.002","article-title":"Problems encountered during anti-tumor necrosis factor therapy","volume":"4","author":"Desai","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2008.11.003_bib21","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2008.11.003_bib22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1086\/508538","article-title":"Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists","volume":"43","author":"Tubach","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.autrev.2008.11.003_bib23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etarnercept Study Group. Etanercept as an adjuvant to interferon and ribavarin in treatment-na\u00efve patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2008.11.003_bib24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","article-title":"Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphoma","volume":"64","author":"Geborek","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2008.11.003_bib25","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/ard.2006.067660","article-title":"All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with TNF antagonists","volume":"66","author":"Carmona","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2008.11.003_bib26","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/ard.2006.062497","article-title":"Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis","volume":"66","author":"Jacobsson","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2008.11.003_bib27","first-page":"1213","article-title":"Treatment with tumour necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"Jacobsson","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2008.11.003_bib28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.autrev.2007.03.009","article-title":"Potential target of infliximab in autoimmune and inflammatory diseases","volume":"6","author":"Atzeni","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2008.11.003_bib29","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","article-title":"Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes","volume":"46","author":"Genovese","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.003_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.003_bib31","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St. Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.003_bib32","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/art.21655","article-title":"Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.003_bib33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/art.21544","article-title":"Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"Suppl 80","key":"10.1016\/j.autrev.2008.11.003_bib34","first-page":"25","article-title":"Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study","volume":"34","author":"Allaart","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2008.11.003_bib35","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","article-title":"Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial","volume":"146","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2008.11.003_bib36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2008.11.003_bib37","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/art.21661","article-title":"Infliximab treatment maintains employability in patients with early rheumatoid arthritis","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.003_bib38","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/ard.2006.054742","article-title":"Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?","volume":"66","author":"Hjardem","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2008.11.003_bib39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"Quinn","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.003_bib40","unstructured":"P. Sarzi-Puttini, M. Antivalle, A. Marchesoni, E.G. Favalli, R. Gorla, M. Fillipini, et al. Efficacy and safety of anti-TNF agents in the Lombardy Rheumatoid Arthritis Network (LORHEN). Reumatismo in press."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997208002218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997208002218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,24]],"date-time":"2018-12-24T04:50:34Z","timestamp":1545627034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997208002218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S1568997208002218"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2008.11.003","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}